for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ascletis Pharma Inc

1672.HK

Latest Trade

3.69HKD

Change

-0.16(-4.16%)

Volume

1,918,000

Today's Range

3.67

 - 

3.89

52 Week Range

3.58

 - 

9.05

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3.85
Open
3.85
Volume
1,918,000
3M AVG Volume
23.96
Today's High
3.89
Today's Low
3.67
52 Week High
9.05
52 Week Low
3.58
Shares Out (MIL)
1,120.69
Market Cap (MIL)
4,314.64
Forward P/E
2,026.32
Dividend (Yield %)
--

Next Event

Ascletis Pharma Inc Annual Shareholders Meeting

Latest Developments

More

Ascletis Pharma Updates On Investigational New Drug Approval

Ascletis Pharma Received Investigational New Drug Approval For Asc18

Singapore's GIC Trims Stake In Ascletis Pharma Inc - HKEx Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ascletis Pharma Inc

Ascletis Pharma Inc. is a China-based company principally engaged in the research and development of biological products. The Company is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

Industry

Biotechnology & Drugs

Executive Leadership

Jinzi Jason Wu

Executive Chairman of the Board, Chief Executive Officer

Judy Hejingdao Wu

Vice President, Executive Director

Yuemei Yan

Vice President of Sales

Yi Chen

Vice President

Lok Kwan Yim

Joint Company Secretary

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, HKD)

2018

0.2K

2019(E)

0.4K
EPS (HKD)

2018

-0.010

2019(E)

-0.001
Price To Earnings (TTM)
--
Price To Sales (TTM)
30.83
Price To Book (MRQ)
1.15
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.16
LT Debt To Equity (MRQ)
0.10
Return on Investment (TTM)
-4.18
Return on Equity (TTM)
-4.02

Latest News

Chinese drugmaker Chipscreen's STAR Market IPO sees feverish demand

Shenzhen Chipscreen Biosciences, which plans to list on China's red-hot new tech board, said its newly issued shares were almost 3,000-times oversubscribed among retail investors, despite an eye-popping offer pricing of 468-times earnings.

UPDATE 2-Shanghai Junshi Biosciences soars on HK debut after $394 mln IPO

* Junshi Biosciences taking advantage of new listing rules in HK

UPDATE 1-China's Junshi Biosciences raises $394 mln after pricing IPO at bottom of range -sources

Chinese biotech startup Shanghai Junshi Biosciences Co Ltd has raised $394 million after pricing its Hong Kong initial public offering (IPO) at the bottom of a marketed range, two people familiar with the share sale said on Monday.

China's Junshi Biosciences raises $394 mln after pricing IPO at bottom of range -sources

Chinese biotech startup Shanghai Junshi Biosciences Co Ltd has raised $394 million after pricing its Hong Kong initial public offering (IPO) at the bottom of a marketed range, two people familiar with the share sale said on Monday.

China biotech Junshi Biosciences seeks up to $414 million in Hong Kong IPO

Chinese biotech company Shanghai Junshi Biosciences is seeking up to $414 million in a Hong Kong initial public offering (IPO), making it the latest company to take advantage of new listing rules to attract early-stage drug developers.

UPDATE 3-China's Innovent Biologics surges in Hong Kong debut

* Market volatility clouding prospects for other IPOs (Adds closing price, analyst comment)

UPDATE 2-China's Innovent prices HK IPO near top end, raises $421 mln -sources

* Company proceeded with IPO due to investor support -CFO (Adds context, company background)

China's Innovent Biologics looks to raise up to $422 mln in HK IPO - sources

Chinese biotech firm Innovent Biologics is looking to raise up to $422 million in its Hong Kong IPO, three sources said, in what could be the biggest biotech IPO in the financial hub this year.

RPT-FOCUS-As China builds biotech sector, cash floods U.S. startups

For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company.

As China builds biotech sector, cash floods U.S. startups

For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company.

Chinese biotech valuations likely hit as trailblazer's Hong Kong shares sink

Biotech startups can expect more measured valuations should they list in Hong Kong, investors and bankers said, after shares of the first such firm to take advantage of rules allowing listings from pre-profit biotechs dropped 44 percent in the first month.

Alibaba-backed online parenting firm Babytree eyeing up to $1 bln HK IPO -sources

* Babytree looking to raise $800 mln to $1 bln in HK IPO -sources

China Tower joins growing list of subdued Hong Kong IPO debuts

China Tower Corp Ltd's <0788.HK> shares closed flat on their debut in Hong Kong on Wednesday, with escalating Sino-U.S. trade tensions dragging on investor sentiment toward the world's biggest initial public offering (IPO) in two years.

UPDATE 1-Trading, IPO surge bumps HKEX first-half net to record high

* H1 net profit HK5.04 billion vs HK$3.49 billion year earlier

Hong Kong exchanges first-half net profit up 44 pct to record

Hong Kong's stock exchange operator said first-half net profit rose 44 percent, thanks to record high revenues from both trading and new listings.

Hong Kong's IPO market braces for China Tower debut after string of poor starts

Hong Kong is readying to host the world's biggest initial public offering (IPO) in two years on Wednesday, as China Tower Corp Ltd <0788.HK> debuts in a market with record IPO numbers but where recent floats have struggled to maintain issue prices.

China's Ascletis closes flat on debut in HK's first float under new biotech rules

Chinese biotech firm Ascletis Pharma Inc <1672.HK> saw its shares end their Hong Kong debut flat on Wednesday after rising as much as 6.4 percent, in the culmination of the city's first listing under new rules designed to attract drug developers.

Chinese biotech Ascletis rallies in HK debut, in test of new market rules

(This version of the story corrects last paragraph to say 3SBio Inc and WuXi Biologics were HK's biggest biotech IPOs, not China Resources Pharma Group.)

HKEX chief welcomes secondary listings while China finalises CDRs

The chief executive of Hong Kong's stock exchange said overseas-listed Chinese firms were welcome to tap the territory's market for funds while waiting for mainland China to implement its own secondary listings plan.

Chinese biotech firm Ascletis set to open higher in HK debut

Shares of Chinese firm Ascletis Pharma Inc were set to open 5.7 percent above their issue price on debut in Hong Kong on Wednesday, the first such listing in the city under new rules designed to attract early-state biotechs.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up